Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Samit
S
Patel
Ann
A
Le
Sunshine
S
Gascon
D000493:Allopurinol / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D007262:Infusions, Intravenous; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000191:economics*; D012189:Retrospective Studies; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000188:drug therapy* / Q000191:economics*; D014503:Urate Oxidase / Q000008:administration & dosage / Q000191:economics*
D011994:Recombinant Proteins; C469709:rasburicase; D000493:Allopurinol; D014503:Urate Oxidase